A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations

被引:25
作者
Alhazmi, Hassan A. [1 ]
Alnami, Ahmed M. [1 ]
Arishi, Mohammed A. A. [1 ]
Alameer, Raad K. [1 ]
Al Bratty, Mohammed [1 ]
Rehman, Zia Ur [1 ,2 ]
Javed, Sadique A. [1 ]
Arbab, Ismail A. [1 ,3 ]
机构
[1] Jazan Univ, Dept Pharmaceut Chem, Coll Pharm, Jazan 45142, Saudi Arabia
[2] Mangalayatan Univ, IBMER, Dept Pharm, 33rd Milestone, Aligarh 202145, Uttar Pradesh, India
[3] Univ West Kordufan, Fac Educ, Dept Chem, El Nahud, West Kordufan S, Sudan
关键词
reversed-phase HPLC; atorvastatin; simvastatin; telmisartan; irbesartan;
D O I
10.3390/scipharm86010001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to develop and validate a fast and simple reversed-phase HPLC method for simultaneous determination of four cardiovascular agents-atorvastatin, simvastatin, telmisartan and irbesartan in bulk drugs and tablet oral dosage forms. The chromatographic separation was accomplished by using Symmetry C18 column (75 mm x 4.6 mm; 3.5 mu) with a mobile phase consisting of ammonium acetate buffer (10 mM; pH 4.0) and acetonitrile in a ratio 40:60 v/v. Flow rate was maintained at 1 mL/min up to 3.5 min, and then suddenly changed to 2 mL/min till the end of the run (7.5 min). The data was acquired using ultraviolet detector monitored at 220 nm. The method was validated for linearity, precision, accuracy and specificity. The developed method has shown excellent linearity (R-2 > 0.999) over the concentration range of 1-16 mu g/mL. The limits of detection (LODs) and limits of quantification (LOQs) were in the range of 0.189-0.190 and 0.603-0.630 mu g/mL, respectively. Inter-day and intra-day accuracy and precision data were recorded in the acceptable limits. The new method has successfully been applied for quantification of all four drugs in their tablet dosage forms with percent recovery within 100 +/- 2%.
引用
收藏
页数:13
相关论文
共 43 条
[1]   Statins as antiinflammatory and immunomodulatory agents - A future in rheumatologic therapy? [J].
Abeles, AM ;
Pillinger, MH .
ARTHRITIS AND RHEUMATISM, 2006, 54 (02) :393-407
[2]  
Al-Adl S.M., 2017, J APPL PHARM, V9, P233
[3]   HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets [J].
Alanazi, Amer M. ;
Abdelhameed, Ali S. ;
Khalil, Nasr Y. ;
Khan, Azmat A. ;
Darwish, Ibrahim A. .
ACTA PHARMACEUTICA, 2014, 64 (02) :187-198
[4]   Determination of irbesartan in the presence of hydrochlorothiazide by derivative spectrophotometry [J].
Albero, I ;
Ródenas, V ;
García, S ;
Sánchez-Pedreño, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (1-2) :299-305
[5]  
Balaji S, 2010, Pak J Pharm Sci, V23, P375
[6]  
Bernard S., 2012, J APPL PHARM SCI, P150, DOI [10.7324/JAPS.2012.2606, DOI 10.7324/JAPS.2012.2606]
[7]  
Chavhan V, 2014, J APP PHARM, V6, P55
[8]  
Ciofu C, 2012, MAEDICA, V7, P337
[9]  
Erk N, 2003, PHARMAZIE, V58, P543
[10]   An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets [J].
Ertürk, S ;
Aktas, ES ;
Ersoy, L ;
Fiçicioglu, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 33 (05) :1017-1023